Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 424 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Targeted Screening Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Feedback on Learning of a Motor Sequence Task

NCT04270448
View directory record Official record
Conditions
Adult
Interventions
Motor Sequence Task
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 40 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

NCT03435380
View directory record Official record
Conditions
Breast Neoplasms, Early Detection of Cancer
Interventions
Patient activation, Primary care physician activation, Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
25 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
New York, New York • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 30, 2026, 10:27 AM EDT
Enrolling by invitation Not applicable Interventional

Book Sharing for Toddlers With Clefts

NCT06338319
View directory record Official record
Conditions
Cleft Palate, Cleft Lip and Palate
Interventions
Book-Sharing for Toddlers with Clefts (BOOST)
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
20 Months to 32 Months
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting No phase listed Observational

Improving Primary Care Access to Urinary Incontinence Treatment for Women Veterans

NCT05438849
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Mobile Health Application focused on behavioral treatments to treat urinary incontinence, Practice Facilitation
Behavioral · Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
20 Years and older · Female only
Enrollment
3,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

NCT06357988
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Radionuclide Imaging, Vismodegib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management

NCT06634810
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Self-Management Support, COPD Education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment

NCT03292705
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
PEP, CCI
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Phase 1 Interventional

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

NCT06815029
View directory record Official record
Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Interventions
Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NCT06031688
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib
Procedure · Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Minutes and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
278
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

Screening For BCRL In Targeted Therapy For Breast Cancer

NCT05142800
View directory record Official record
Conditions
Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Lymphedema of Upper Limb, Lymphedema of the Hands, Edema, Edema Arm, Breast Cancer Lymphedema, Breast Cancer Metastatic, Breast Cancer Stage, Breast Cancer
Interventions
Perometer, SOZO device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 4 Interventional

Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)

NCT03603912
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Metformin, Lifestyle/Risk Factor Modification
Drug · Behavioral
Lead sponsor
Mina Chung, MD
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Target ALS Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Georgetown, District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

NCT04556136
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
Standing Phototherapy Kiosk, D3 Oral supplement
Device · Dietary Supplement
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial

NCT06565416
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions
Implementation Strategies
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Arcata, California • Minneapolis, Minnesota • Toppenish, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Staying Healthy Through Education and Prevention Study

NCT00817193
View directory record Official record
Conditions
Disability
Interventions
Physical Activity, Wellness
Behavioral
Lead sponsor
LeadingAge
Other
Eligibility
65 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Mountain Home, Arkansas • Loveland, Colorado • DeLand, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

NCT07406490
View directory record Official record
Conditions
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions
Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 79 Years
Enrollment
6,466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Active Bathing to Eliminate Infection (ABATE Infection) Trial

NCT02063867
View directory record Official record
Conditions
Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions
Arm 2: Decolonization
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
52
States / cities
West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The STop UNhealthy Substance Use Now Trial

NCT06524232
View directory record Official record
Conditions
Risky Health Behavior, Substance Use Disorders, Substance Abuse, Alcohol Use Disorder, Drinking, Alcohol, Substance Use
Interventions
Practice Facilitation (PF), Learning Collaborative (LC), Performance Incentives (PI)
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on Pairing Sedation Strategies and Weaning

NCT02219659
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Sedation Protocol with Daily Interruption, Sedation Protocol Without Daily Interruption, Fentanyl Push First
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 30, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328
View directory record Official record
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Selumetinib Sulfate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 10:27 AM EDT
Completed No phase listed Observational

Targeting Infant Development With Early Screening

NCT04326179
View directory record Official record
Conditions
Development, Child
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Up to 3 Years
Enrollment
7,720 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 30, 2026, 10:27 AM EDT